Skip to main content

Advertisement

Table 2 Anticoagulant use outcomes in the study period

From: Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis

  IMS MarketScan Commercial MarketScan Medicare Optum Medicaid
All patients, N 30,757 21,976 38,643 9,120 4,901
Patients receiving anticoagulant by stroke risk* and age category, N (%)      
All Stroke Risk Levels 11,382 (37%) 6,444 (29%) 14,686 (38%) 3,595 (39%) 803 (16%)
High Risk 6,832 (43%) 1,934 (39%) 9,822 (40%) 1,946 (51%) 566 (19%)
 Age <65 years 1,252 1,877 58 672 476
 Age: 65–74 years 1,484 57 1,651 386 38
 Age ≥ 75 years 4,090 0 8,113 888 52
Moderate Risk 3,130 (34%) 2,415 (31%) 3,788 (36%) 1,091 (36%) 172 (13%)
 Age <65 years 1,149 2,311 34 696 158
 Age: 65–74 years 1,213 104 1,600 292 11
 Age ≥ 75 years 764 0 2,154 103 3
Low Risk 1,420 (25%) 2,095 (23%) 1,076 (33%) 558 (25%) 65 (12%)
 Age <65 years 813 1,940 12 423 63
 Age: 65–74 years 603 155 1,064 135 2
 Age ≥ 75 years 0 0 0 0 0
Anticoagulant MPR      
MPR 0.58 0.58 0.66 0.61 0.72
Gap in Anticoagulation Therapy      
Patients with a Gap in Anticoagulation Therapy, N(%) 6,745 (59%) 3,828 (59%) 6,687 (46%) 1,883 (52%) 233 (29%)
Average Time to First Gap in Anticoagulation Therapy (days) 132 150 157 144 129
  1. MPR – Medication Possession Ratio.
  2. *CHADS2 used to determine stroke risk.